Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.98), $0.27 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Putin Said To Plan Ukraine Escalation, Seeing Talks Fruitless - Bloomberg
• Freedom Broker Downgrades CF Industries (CF) to Hold, 'Strong Half, Softer Base Ahead'
• J. M. Smucker (SJM) Tops Q1 EPS by 103c